news

CUPERTINO, Calif., July 11 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) today reported that patient recruitment has been completed in the pivotal Phase III study with Remoxy(TM), an abuse resistant pain medicine under development based on DURECT’s patented ORADUR(TM) technology incorporating the opioid oxycodone. This event was announced today by Pain Therapeutics, Inc. (Nasdaq: PTIE) and […]

CUPERTINO, CA, June 27, 2007/ PRNewswire-First Call via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that Endo Pharmaceuticals Inc. (Nasdaq: ENDP) has commenced its Phase II clinical program designed to evaluate the conversion of patients being treated with various opioids to sufentanil patches utilizing DURECT’s TRANSDUR™ technology. DURECT had previously announced positive results from

CUPERTINO, Calif., June 21, 2007 /PRNewswire-FirstCall via COMTEX News Network/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Jefferies Healthcare Conference being held in New York City. Matthew J. Hogan, Chief Financial Officer, will be presenting at the conference on June 27, 2007 at 9:10 AM Eastern Time. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

CUPERTINO, Calif., June 11 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Sixth Annual Biotechnology and Medical Technology Conference being held at the New York Palace Hotel in New York City. Matthew J. Hogan, Chief Financial Officer, will be presenting at the conference on June 14, 2007 at 2:30

CUPERTINO, Calif., May 17 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that Voyager Pharmaceutical has provided its shareholders with an update on its truncated Phase 3 clinical trial for Memryte, an investigational drug for the treatment of Alzheimer’s disease. Voyager has informed its shareholders that they have observed positive outcome trends among women, but

CUPERTINO, Calif., May 8 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it would present at the Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference to be held on May 14-15 at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco. James E. Brown, President and CEO, will be presenting at

CUPERTINO, Calif., May 7 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2007. Total revenues were $5.7 million for the three months ended March 31, 2007, compared to $5.2 million for the same period in 2006. Net loss for the three months ended March 31, 2007

CUPERTINO, Calif., May 1 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the 2007 UBS Global Generic and Specialty Pharmaceuticals Conference being held at the Grand Hyatt Hotel in New York City. Matthew J. Hogan, Chief Financial Officer, will be presenting at the conference on May 8th at 2:30 p.m.

CUPERTINO, Calif., April 30 /PRNewswire-FirstCall/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) first quarter 2007 financial results press release, you are invited to listen to the conference call that will be broadcast live over the Internet on Monday, May 7th 2007 at 4:30 p.m. EDT. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) A live audio webcast of the

CUPERTINO, Calif., April 9, 2007 /PRNewswire-FirstCall via COMTEX News Network/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the CIBC Biotechnology & Specialty Pharmaceuticals Conference being held at the Millenium Broadway Hotel in New York City. Matthew J. Hogan, Chief Financial Officer, will be presenting at the conference on April 11